2003, Number 3
<< Back Next >>
Rev Mex Pediatr 2003; 70 (3)
Use of alpha-dornase in the management of difficult resolution athelectasia in the newborn
Alanís GSG, López GV, Rodríguez BI, Abrego MV
Language: Spanish
References: 7
Page: 143-145
PDF size: 50.76 Kb.
ABSTRACT
The experience obtained with the employment of alpha-dornase in two neonates with atelectasis, it is reported. Emphasis is done about the effectiveness and security of this medication in illnesses characterized by thickening of mucous secretions and particularly in neonates with atelectasia, when the conventional treatment fail.
REFERENCES
El Hassan NO, Chess PR, Huysman MW, Merkus PFJ. Rescue use of DNase in critical lung atelectasis and mucus retention in premature neonates. Pediatrics 2001; 108(2): 468-470.
Potter JL, Spector S, Mattehew LW, Lemm J. Studies on pulmonary secretion: the nucleic acids in whole pulmonary secretion from patients with cystic fibrosis, bronchiectasis and laryngectomy. Am Rev Respir Dis 1969; 9: 909-996.
Shak S, Capon DJ, Helmiss R, Marsters SA, Baker CL. Recombinant human DNase reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990; 87: 9188-9192.
Touleimat BA, Conoscenti CS, Fine JM. Recombinant of lobar atelectasis due to retained secretions. Thorax 1995; 50: 1319-1321.
Fuchs HJ, Borowitz DS, Christansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and pulmonary function in patients with cystic fibrosis. N Engl J Med 1994; 331: 637-642.
Aitken ML, Burke W, McDonald G, Shak S, Montgomery AB, Smith A. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. JAMA 1992; 267: 1947-1951.
Greally P. Human recombinant DNase for mucus plugging in status asthmaticus. Lancet 1995; 346: 1423-1424.
Full text